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Abstract
Background and Aims: In a previous report, we characterized a condition of gluten sensitivity in juvenile rhesus macaques
that is similar in many respects to the human condition of gluten sensitivity, celiac disease. This animal model of gluten
sensitivity may therefore be useful toward studying both the pathogenesis and the treatment of celiac disease. Here, we
perform two pilot experiments to demonstrate the potential utility of this model for studying intestinal permeability toward
an immunotoxic gluten peptide and pharmacological detoxification of gluten in vivo by an oral enzyme drug candidate.
Methods: Intestinal permeability was investigated in age-matched gluten-sensitive and control macaques by using mass
spectrometry to detect and quantify an orally dosed, isotope labeled 33-mer gluten peptide delivered across the intestinal
epithelium to the plasma. The protective effect of a therapeutically promising oral protease, EP-B2, was evaluated in a
gluten-sensitive macaque by administering a daily gluten challenge with or without EP-B2 supplementation. ELISA-based
antibody assays and blinded clinical evaluations of this macaque and of an age-matched control were conducted to assess
responses to gluten.
Results: Labeled 33-mer peptide was detected in the plasma of a gluten-sensitive macaque, both in remission and during
active disease, but not in the plasma of healthy controls. Administration of EP-B2, but not vehicle, prevented clinical relapse
in response to a dietary gluten challenge. Unexpectedly, a marked increase in anti-gliadin (IgG and IgA) and anti-
transglutaminase (IgG) antibodies was observed during the EP-B2 treatment phase.
Conclusions: Gluten-sensitive rhesus macaques may be an attractive resource for investigating important aspects of celiac
disease, including enhanced intestinal permeability and pharmacology of oral enzyme drug candidates. Orally dosed EP-B2
exerts a protective effect against ingested gluten. Limited data suggest that enhanced permeability of short gluten peptides
generated by gastrically active glutenases may trigger an elevated antibody response, but that these antibodies are not
necessarily causative of clinical illness.
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Introduction
Celiac disease is an inheritable enteropathy caused by dietary
gluten from common food grains such as wheat, rye, and barley [1].
Unlikemostotherdietaryproteins,glutenisincompletelydigestedby
gastrointestinal proteases, yielding proteolytically resistant peptides
that trigger a deleterious immune response in genetically susceptible
individuals [2]. To widely varying degrees in celiac patients, this
immune response produces intestinal effects, such as mucosal
damage, malabsorption, and clinical diarrhea, as well as systemic
humoral effects, such as the production of anti-gliadin antibodies
(AGA) and anti-transglutaminase 2 (TG2) autoantibodies [3,4]. The
only existing therapy for celiac disease is a gluten-free diet, which is
effective in most celiac patients when strictly followed [5]. However,
the maintenance of this diet is extremely difficult due to the ubiquity
of gluten in most human diets, and relapse due to accidental
ingestion of gluten contained in inadequately labeled or gluten-
contaminated foods isan abiding concernand a frequent occurrence
for treated celiac patients [6–9].
Several properties of immunogenic gluten peptides have been
identified as being critical toward their pathogenic role in celiac
disease [10]. These include proteolytic resistance due to high
proline and glutamine content [2,11], presence of preferred
glutamine residues for TG2-mediated glutamine deamidation
[12,13], and high affinity of these deamidated sequences for
human leukocyte antigen (HLA)-DQ2 [14,15], a class II major
histocompatibility complex (MHC) molecule associated with over
90% of diagnosed celiac patients [16,17]. Additionally, longer
peptides containing multiple epitopes appear to be more
immunotoxic than their constituent epitopes [2,18]. One peptide
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proteolysis of a2-gliadin, possesses all of these characteristics and
activates proliferation in all celiac patient-derived T cell lines
tested so far [2,19]. Moreover, this peptide is detected as a stable
digestive product of ingested gluten in both rats [20] and
cynomolgus monkeys (MTB, unpublished results), suggesting it is
likely produced from dietary gluten in the human gut as well. It is
therefore presumed that the 33-mer is important in the induction
and propagation of the adverse response to gluten in celiac disease
patients. To enact such a role in vivo, however, this relatively large
(,4 kDa) peptide must be transported intact across the mucosal
epithelium to the underlying lymphoid tissue where it can be
presented by DQ2 on antigen presenting cells to gluten-specific
CD4+ T cells.
Despite strong evidence implicating gluten peptides in celiac
disease pathogenesis, the detection of a chemically-defined gluten
peptide in extra-intestinal body fluids following oral dosing has yet
to be reported, and the extent to which disease state alters
permeability toward such a peptide is unclear. It is well established
that active enteropathy is associated with structurally altered tight
junctions [21] and increased permeability toward small (,1 kDa)
non-permeating molecules [22–26], and that these defects are not
completely resolved by a gluten-free diet [21,23–25]. However, it
is unclear whether these findings will translate to increased
permeability toward gluten peptides of sufficient size to elicit an
immune response. Further, studies of intestinal permeability with
respect to disease state in celiac patients are hampered by the
practical difficulty of ensuring strict dietary exclusion of gluten [6–
9]. An animal model of gluten sensitivity could enable the
observation and study of transepithelial gluten peptide delivery in
an in vivo system in which dietary gluten content can be absolutely
controlled. Furthermore, such an animal model could facilitate
preclinical testing of pharmacological therapies aimed at protect-
ing celiac patients from the constant risk of dietary gluten
exposure.
In a previous report, we characterized a condition of gluten
sensitivity in juvenile rhesus macaques (Macaca mulatta) that is
similar in many respects to celiac disease [27]. Affected animals
exhibited intestinal lesions, malabsorptive steatorrhea, clinical
diarrhea, and elevated anti-gliadin (though not anti-TG2)
antibodies in response to a gluten-containing diet. Administration
of a gluten-free diet to one such affected animal, FH09, caused
complete remission, whereas reintroduction of dietary gluten
caused clinical, histological, and serological relapse. Similar
dietary changes had no effect on an age-matched control, FR26.
In this report, we conduct two pilot studies using the gluten-
sensitive macaque model. The first study investigates the
fundamental question of whether the immunotoxic 33-mer peptide
is delivered intact across the intestinal epithelium in gluten-
sensitive FH09, during both remission and relapse, as well as in
healthy control FR26. We use mass spectrometry to detect for the
first time the transepithelial delivery of a chemically-defined,
immunotoxic gluten peptide in a gluten-sensitive organism. The
second study investigates the practical question of whether oral
protease therapy can protect a second gluten-sensitive animal,
FH45, from gluten challenge-induced relapse. We present
clinical and serological data for FH45, and for control FI96,
showing that EP-B2, a gluten-specific endoprotease with
potential as a therapeutic for celiac disease [20,28–30], prevents
clinical relapse in FH45 in response to a gluten challenge.
However, this treatment gives rise to an unexpected elevation in
anti-gliadin and anti-TG2 antibodies, the implications of which
are discussed.
Methods
Rhesus macaques
Gluten-sensitive juvenile macaques, FH09 and FH45, were
selected for dietary treatment and pilot experiments from a
population of rhesus macaques exhibiting clinical diarrhea and
elevated AGA on a gluten-containing diet [27]. Age-matched
controls, FR26 and FI96, were selected from a panel of AGA-
negative, healthy rhesus macaques tested in the same study.
Animals were housed for 10 months under biosafety level two
conditions in accordance with the standards of the Association for
Assessment and Accreditation of Laboratory Animal Care.
Investigators adhered to the Guide for the Care and Use of
Laboratory Animals prepared by the National Research Council.
Gluten-containing and gluten-free diets
The gluten-containing and gluten-free diets used in this study
were previously described [27]. Animals would typically consume
4% of their body weight daily (e.g. 160 g of food for a 4 kg
animal).
Veterinary procedures: 33-mer intragastric inoculation, EP-B2 adminis-
tration, peripheral blood collection, and clinical evaluation.
Study 1. Gluten-sensitive FH09 and control FR26 were
administered a gluten-free diet until FH09 was negative for AGA
and in clinical remission [27]. A dose of 25 mg (6.5 mmol) of
isotopically labeled 33-mer (
D333-mer) dissolved in 10 ml of
Gatorade was administered directly into the stomach of FH09 by
intragastric tube. A 0.5 ml sample of EDTA-blood was collected
froman earveinat 0,30, 60, 120, and180 min following the 33-mer
inoculation. Dietary gluten was then reintroduced for 10 weeks until
FH09 was AGA-positive and in clinical relapse [27]. A dose of
25 mg of
D933-mer was administered exactly as described above to
FH09and FR26,and EDTA-bloodwascollectedfromanearveinat
0, 60, 120, 180, and 240 min following 33-mer inoculation. Animals
were fasted at least 2 h prior to peptide inoculations. Blood
collections and 33-mer inoculations were performed with sedated
and anesthetized animals.
Study 2. Gluten-sensitive FH45 and control FI96 were
switched from a gluten-containing to a gluten-free diet at week
0, re-challenged with the gluten-containing diet from week 10.4 to
11.4, and then returned to a gluten-free diet for the remainder of
the experiment. To test whether orally administered EP-B2 can
prevent clinical symptoms resulting from gluten challenge, animals
were fed a gluten-free diet with the addition of a daily slice of
unbleached wheat bread (,4 g gluten) for 8 weeks (weeks 22.9 to
30.9), during the first 4 of which (weeks 22.9 to 26.9) gluten-
sensitive macaque FH45 received a daily dose of 2 g recombinant
proEP-B2 dissolved in an electrolyte drink immediately prior to
bread consumption. Recombinant proEP-B2 was expressed and
purified as previously described [28,31]. Peripheral blood samples
(1 ml) were collected every 1–2 weeks from a femoral vein, and
plasma was harvested and stored at 280
oC until analyzed for
AGA and anti-TG2 antibodies. Clinical health was monitored as
previously described [27]. Briefly, daily clinical scores were
averaged over weekly intervals to obtain each weekly
mean6standard deviation. Criteria for clinical scoring (1–6
scale) were scaled relative to ‘‘clinically normal’’, age-matched
controls, i.e. score of 1. Score 2 corresponded to beginning of
diarrhea, i.e. pasty stools. Score 3 corresponded to semi-liquid
stools and decreased activity. Score 4 corresponded to liquid
stools, decreased activity, moderate dehydration and ‘‘balloon’’
stomach. Score 5 corresponded to liquid stools, depression, severe
dehydration and balloon stomach. Score 6 corresponded to a
moribund animal where prompt euthanasia is recommended.
Gluten Sensitivity Studies
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ELISA assays were performed as previously described [27].
Peptide detection via 3Q LC-MS/MS
Unlabeled and isotopically labeled 33-mer peptides
(LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF; positions
3,11, and 25 underlined) were synthesized on solid-phase using
Boc/HBTU chemistry, purified post-cleavage by reverse-phase
HPLC, and lyophilized as previously described [18]. Deuterium
labels were introduced by incorporating [5,5,5-D3]-leucine (Cam-
bridge Isotope Laboratories, Inc.) at position 11 (
D333-mer), or at
positions 3, 11, and 25 (
D933-mer) during synthesis. The identity of
each purified peptide was confirmed by electrospray mass
spectrometry prior to lyophilization. Following peptide dosing
and peripheral plasma collection, described above, plasma
proteins were precipitated by addition of acetonitrile. Plasma
was mixed with an equal volume of cold acetonitrile+0.1% formic
acid, vortexed, incubated for 2 h at 4uC, and centrifuged at
14,000Ng for 10 min at 4uC. The supernatant was mixed with an
equal volume of 0.1% formic acid to dilute the acetonitrile
concentration, and 100 ml of each supernatant was injected on 3Q
LC-MS/MS. When quantitation was performed, unlabeled 33-
mer was spiked into the plasma samples prior to acetonitrile
precipitation as an internal control (5 pmol/100 ml injection) and
injections were performed at least in triplicate.
Massspectrometryanalysiswasperformed aspreviouslydescribed
[20] with the following modifications. For
D333-mer detection,
positive ion SRM mode was used for monitoring the transitions of
ions at m/z 979.5
4+R263.4
+ (30V cone voltage, 27eV collision
energy) and m/z 1305.6
3+R263.1
+ (40V cone voltage, 50eV
collision energy). For
D933-mer, the transitions monitored were
m/z 981.0
4+R263.1
+ (30V cone voltage, 27eV collision energy.) for
the quantitation assayandm/z1307.7
3+R263.1
+ (40Vcone voltage,
50eV collision energy) as a confirmatory transition. For unlabeled
33-mer internal standard, the transitions monitored were m/z
978.8
4+R263.1
+ (30V cone voltage, 27eV collision energy) for the
quantitation assay and m/z 1304.7
3+R263.1
+ (40V cone voltage,
50eV collision energy) as a confirmatory transition. It was confirmed
that plasma samples yielded no signal from unlabeled 33-mer
transitions absent internal standard spiking. Levels of
D933-mer in
each sample were determined by comparison of the area under the
D933-mer transition peak to the area under the internal standard
transition peak. To enable statistical evaluation in cases where the
D933-mer peak area was below threshold but the internal standard
was detected, below-threshold
D933-mer peak areas were assigned
the threshold value.In all suchinstances, this resulted ina narrowing
of the difference between FH09 samples and time-matched FR26
controls.
Statistical evaluation
Statistical differences between the level of plasma
D933-mer in
FH09 and FR26 at matched timepoints following oral dosing were
determined by Student’s t-test assuming equal variances. A p value
of ,0.05 was considered significant.
Results
Study 1: Intestinal permeability toward orally dosed 33-
mer
Detection of ingested gluten peptide in the plasma of a
gluten-sensitive macaque in remission. Gluten-dependent
enteropathy in gluten-sensitive macaques and celiac patients does
not necessarily require absorption of gluten peptides across the
epithelium, since gluten peptides have been shown to induce
epithelial damage directly via the innate immune pathway [32].
However, the adaptive humoral immune response raised against
gluten in both macaques and humans suggests that gluten peptides
are delivered intact across the intestinal epithelium, thus gaining
access to the underlying lymphoid tissue. Despite this, the
detection of an intact, chemically-defined gluten peptide in an
extra-intestinal compartment following oral ingestion has yet to be
reported. To address this, we orally dosed a synthetic, isotopically
labeled gluten peptide to gluten-sensitive macaque FH09 in
remission, and measured peripheral plasma peptide levels over
time via mass spectrometry. A dose of 25 mg (6.5 mmol) of triply
deuterated 33-mer (
D333-mer) dissolved in 10 ml of electrolyte
drink was administered intragastrically to FH09, and plasma
samples were collected from an ear vein at 0, 30, 60, 120, and
180 min following gavage. Following acetonitrile precipitation of
plasma proteins,
D333-mer content was assessed by selected
reaction monitoring (SRM) analysis using high-performance
liquid chromatography-coupled triple quadrupole tandem mass
spectrometry (3Q LC-MS/MS). The peptide was detected in
plasma collected at 180 minutes after oral dosing, but was not
detected in earlier post-dose samples, nor in plasma collected prior
to dosing (Figure 1). By comparison to a 5 pmol standard injected
in parallel, the isotopically labeled peptide was estimated to be at
nanomolar concentrations in the plasma. Since SRM analysis
requires that selected precursor ions, as well as expected fragment
ions, be detected in order to constitute a transition signal, the
detection of
D333-mer signal in a plasma sample following oral
dosing demonstrates that ingested
D333-mer was delivered intact
across the intestinal epithelium. As the peptide was dosed to FH09
following adherence to a gluten-free diet, at which point the
mucosa had ostensibly recovered [27], this finding implies that the
gluten-sensitive macaque gut remains permeable to large
(,4 kDa) gluten peptides even in a state of remission.
33-mer is absorbed by a gluten-sensitive macaque but not
by a healthy control. To determine how disease state affects
the transepithelial delivery of intact gluten peptides, we induced
clinical relapse in FH09 by reintroduction of dietary gluten for
10 weeks [27], then performed a second peptide dosing
experiment with FH09 in a state of active enteropathy and with
FR26 as a healthy control. In this experiment, we used
D933-mer,
rather than
D333-mer, to provide a large enough difference
between the mass of our test peptide and that of an unlabeled 33-
mer internal standard, thereby enabling quantitation. Both FH09
and FR26 were dosed with 25 mg of isotopically labeled peptide
(
D933-mer), and peripheral plasma samples were collected as
before at 0, 60, 120, 180, and 240 minutes. Serosal
D933-mer
peptide was detected at 60 minutes, and possibly at 120 minutes,
following oral dosing in FH09, but was not detected above
background levels at any timepoint in the healthy control FR26
(Figure 2). By comparison to the internal standard, we calculated
the concentration of
D933-mer in peripheral plasma at 60 minutes
to be 7.060.4 nM. Since FH09 weighed 2.58 kg at this point, and
therefore had approximately 260 ml of peripheral blood, we
estimate that ,0.1% of the 6.5 mmol ingested peptide was
delivered intact across the intestinal epithelium.
Study 2: Pharmacological protection from gluten
challenge by oral enzyme therapy
Oral glutenase therapy can prevent clinical relapse in
response to dietary gluten. Orally administered proteases
capable of digesting immunotoxic gluten peptides constitute a
promising potential therapy for celiac disease [33,34]. Recently,
barley endoprotease EP-B2 was shown to destroy immunotoxic
gluten epitopes, including those present in the 33-mer [28],
Gluten Sensitivity Studies
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derived, gluten-reactive T cells [29]. Due to the lack of an animal
model for celiac disease, evaluation of enzyme efficacy in vivo has
been limited to experiments performed in rats, which are not
gluten-sensitive, requiring that digested material be removed from
the alimentary tract and tested for immunogenicity ex vivo [20].
This approach cannot therefore address a central consideration of
oral protease therapy regarding the kinetics of deleterious
responses to ingested gluten versus the kinetics of glutenase-
catalyzed detoxification. Preclinical demonstration of EP-B2
efficacy in a gluten-sensitive organism would benefit the
evaluation of this enzyme as a potential drug candidate.
To identify a gluten-sensitive macaque for this study, and to
corroborate the gluten-dependence of clinical and serological signs
and symptoms observed in FH09 [27], we administered a gluten-
free diet to FH45, an AGA+ macaque with chronic diarrhea of
lesser severity compared with FH09, as well as to FI96, an age-
matched control macaque without AGA or clinical symptoms in
response to gluten. Similar to FH09, the administration of a
gluten-free diet resulted in clinical remission in FH45 within
6 weeks, over which time AGA levels also returned to baseline
values (Figure 3). Upon transient re-introduction of gluten (week
10.4–11.4), FH45 relapsed clinically and exhibited low levels of
AGA, both of which recovered once again with return to a gluten-
free diet (Figure 3A and B). As with previous control FR26 [27],
control FI96 exhibited no clear clinical responses to these dietary
changes (Figure 3D).
To determine whether oral enzyme therapy can prevent clinical
responses to a dietary gluten challenge in an otherwise gluten-free
diet, we initiated our pilot study with gluten-sensitive FH45 in a state
of clinical remission (week 22.9). At this point, we supplemented the
gluten-free diet fed to macaques FH45 and FI96 with a daily dose of
gluten (slice of wheat bread) for 8 weeks, during the first 4 of which
FH45 additionally received a daily dose of EP-B2 immediately
preceding bread consumption. Clinical health and antibody levels
were monitored during this period (Figure 3). Importantly, FH45
remained clinically healthy while being administered EP-B2 over the
first 4 weeks of this gluten challenge, even though previous gluten
challenges in FH45 and FH09 resulted in rapid (1–2 weeks) relapse
(Figure 3A and [27]). Indeed, FH45 displayed signs of clinical illness
,1 week after EP-B2 dosing was concluded, and continued to
exhibitsporadic diarrhea over the remainder of the gluten challenge.
By contrast, FI96 did not respond clinically to wheat bread
supplementation (Figure 3D).
Oral glutenase therapy causes increased production of
AGA and anti-TG2 antibodies. Although we expected AGA in
FH45 to remain low during EP-B2 treatment, we instead observed
a striking inverse correlation between clinical score and AGA
levels, with AGA increasing during EP-B2 treatment, and
declining thereafter, even while wheat bread dosing continued.
The gluten dose from wheat bread supplementation was ,10% of
that received from the gluten-containing diet, yet AGA levels were
substantially higher (,3-fold) in FH45 duing wheat bread/EP-B2
administration than they were in response to the gluten-containing
diet fed prior to our experiments (Figure 3B, week 0). Even more
Figure 1. Detection of an oral gluten peptide in the peripheral plasma of gluten-sensitive rhesus macaque FH09 during remission.
Plasma samples collected at indicated timepoints following intragastric administration of
D333-mer to FH09 (in remission) were analyzed by 3Q LC-
MS/MS, monitoring for the m/z 979.5
4+R263.4
+ transition in the positive ion SRM mode. Peak intensities are scaled relative to the highest peak in
each chromatogram. Absolute intensities are indicated to the right of the ordinate axis. A
D333-mer peptide reference exhibits the same retention
time and ion transitions as the peptide detected in the 180 min plasma sample.
doi:10.1371/journal.pone.0001857.g001
Figure 2. Intact absorption of an oral gluten peptide in gluten-
sensitive rhesus macaque FH09 but not in healthy control
FR26. Plasma samples collected at indicated timepoints following
intragastric administration of
D933-mer to FH09 (with active enterop-
athy) and FR26 were analyzed by 3Q LC-MS/MS. Plasma concentrations
of
D933-mer were determined by comparison to an unlabeled 33-mer
internal standard. Mean6SD displayed from at least 3 injections.
*P,0.05, ****P,0.00005.
doi:10.1371/journal.pone.0001857.g002
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the course of EP-B2 treatment (Figure 3C), though these were not
observed in gluten-sensitive macaques on a gluten-containing diet
absent EP-B2 treatment (Figure 3C and [27]). Like AGA, the level
of anti-TG2 IgG correlated inversely with clinical score, declining
once EP-B2 treatment ended and diarrhea ensued due to
continued gluten challenge. The implications of these
unexpected findings are discussed below.
Discussion
We exploited the gluten-sensitive rhesus macaque model to
study two questions regarding gluten sensitive enteropathy that
have not yet been investigated in humans or any other model
organism. First, can appreciable quantities of immunotoxic gluten
peptides be absorbed intact across the enterocyte barrier in gluten-
sensitive animals? And second, can oral glutenases provide clinical
benefit to these animals upon gluten exposure?
Toinvestigate gastrointestinalabsorptionofintactglutenpeptides,
we dosed a gluten-sensitive macaque with an isotopically labeled
form of the immunotoxic 33-mer gluten peptide [13], and measured
its plasma concentration using a sensitive and specific mass
spectrometric method. Nanomolar concentrations of the peptide
were measured in peripheral blood, both in remission (gluten-free
diet) as well as in active disease (gluten challenge), but not in control
animals. Although the concentration of the 33-mer peptide in the
intestinal mucosa is likely to be higher, low nanomolar concentra-
tions of the 33-mer peptide are sufficient to stimulate proliferation of
celiac patient-derived T cells in culture [2,19]. Thus, gluten-sensitive
macaques appear to exhibit enhanced intestinal permeability akin to
celiac disease patients. If so, they may offer a unique opportunity to
investigate the mechanisms underlying transport of immunotoxic
gluten peptides across the enterocyte barrier, as well as the relevance
of this aspect of celiac disease to overall disease pathogenesis.
We also took advantage of these gluten-sensitive macaques to
evaluate the clinical and serological efficacy of a therapeutically
Figure 3. Oral enzyme therapy prevents clinical relapse but increases plasma AGA and anti-TG2 IgG in gluten-sensitive rhesus
macaque FH45. Gluten-sensitive FH45 (A-C) and control FI96 (D-F) were switched from a gluten-containing to a gluten-free diet at week 0, re-
challenged with the gluten-containing diet from week 10.4 to 11.4, and then returned to a gluten-free diet for the remainder of the experiment.
During week 22.9-30.9, the gluten-free diet was supplemented with a daily slice of wheat bread. FH45 additionally received a daily dose of EP-B2
glutenase during the first half of this period (week 22.9-26.9). Clinical scores (A,D), anti-gliadin antibodies (B,E), and anti-TG2 antibodies (C,F) were
monitored over the course of the experiment. Levels of IgG (blue; open circles) and IgA (red; open squares) antibodies are provided on the left and
right ordinates, respectively. Clinical score criteria are described in Methods.
doi:10.1371/journal.pone.0001857.g003
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the zymogen form of barley endoprotease EP-B2 have been
extensively investigated as a stand-alone drug candidate [20,28]
and in combination with complementary glutenases [29,30]. Our
study revealed that clinically achievable oral doses of the EP-B2
proenzyme, but not placebo, could prevent dietary gluten from
precipitating clinical relapse in a gluten-sensitive macaque.
Remarkably, however, the levels of anti-gliadin antibodies (IgG
and IgA) underwent a dramatic increase, and, for the first time, we
observed an anti-TG2 antibody (IgG only) response to dietary
gluten in macaques. We speculate that the spike in anti-gliadin
antibody levels is due to delivery of a high dose of short gluten
peptides into a permeable duodenum upon gastric emptying.
Although these shorter peptides are expected to exhibit diminished
T cell reactivity, their small size enables them to penetrate the
enterocyte barrier more efficiently than the considerably longer
peptides produced in the absence of EP-B2. In turn, systemic
distribution of these absorbed peptides could elicit an anti-TG2
IgG response because even short gluten peptides (e.g. pentamers)
are good substrates of mammalian TG2 [35–37]. If so, our
findings have two important implications. First, if the goal of oral
glutenase therapy is to protect a celiac disease patient from all
gluten responses, including anti-gliadin and anti-TG2 antibodies,
then gluten must be extensively proteolyzed in the stomach, not
simply rendered non-reactive towards disease-specific Th1 cells.
The use of combination enzyme therapies that cleave gluten into
very short peptides may be beneficial in this regard [29,30].
Regardless, our data suggest that careful monitoring of patient
antibody levels is warranted in future clinical trials for glutenase
therapies. Second, there has been considerable debate over the
role of anti-TG2 antibodies in celiac disease pathogenesis. For
example, celiac IgG and IgA antibodies inhibit TG2 activity in situ
[38], and subepithelial deposition of IgA class antibodies is
targeted against TG2 in vivo [39], suggesting that anti-TG2
antibodies may impede the physiological function of TG2. On the
other hand, the existence of IgA-deficient celiac patients, as well as
the apparent normal intestinal development in TG2 knockout
mice [40], argues instead that these antibodies may not be
causative of disease. Although we were unable to detect anti-TG2
IgA (suggesting the autoantibodies observed in FH45 were from an
extra-intestinal source), our data appears to support the latter
hypothesis because the clinical symptoms of this gluten-sensitive
macaque correlated inversely with antibody levels.
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